← Back

UroGen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

Price · split & dividend adjusted
News & notes moving URGN
URGN▲

Biotech Stocks Surge on Earnings and Debuts

Several biotech companies posted sharp gains on Wednesday, led by Attovia Therapeutics' 28% surge on its Nasdaq debut and American Well's 25% jump after narrowing its quarterly loss. Attovia priced its IPO at $17 per share and closed at $21.90, while American Well reported a net loss of $9.6 million, or $0.59 per share, down from $19.5 million, or $1.24 per share, a year earlier, though revenue fell to $52.0 million from $70.9 million. Perrigo swung to a net income of $74.5 million, or $0.53 per share, from a loss of $8.4 million, or $0.06 per share, despite a slight revenue dip to $1.02 billion. UroGen Pharma climbed over 16% after total revenue more than doubled to $72.5 million, driven by its bladder cancer drug ZUSDURI, and its net loss narrowed to $14.4 million from $49.9 million. Geron rose 21% as net product revenue increased to $57.5 million from $49.0 million, fueled by higher RYTELO sales, and it forecast full-year RYTELO revenue of $220 million to $240 million.
AMWL ▲GERN ▲PRGO ▲URGN ▲
RTTNews·21dRead more ▾
URGN2

UroGen Pharma Chief Medical Officer Sold $400,000 in Stock After 191% Run

UroGen Pharma's Chief Medical Officer Mark Schoenberg sold 10,000 ordinary shares for $400,000 on July 9, 2026, according to an SEC filing. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted in August 2025 and represents the final transaction of that plan. Schoenberg continues to hold 119,763 shares directly, valued at approximately $4.82 million based on the $40.23 closing price that day. The transaction occurred with UroGen's market capitalization at $2.0 billion, following a 191% stock surge over the prior year, and as the company reported trailing 12-month revenue of $140.5 million and a net loss of $133.2 million. The company's first-quarter revenue jumped 152% to $51 million, driven by the launch of its new bladder cancer therapy Zusduri, which contributed $29.2 million after a permanent insurance billing code took effect.
URGN
The Motley Fool·45dRead more ▾
URGN▲

5 Biotech Stocks That Delivered 100% To 300% Gains

Five biotech stocks highlighted in RTTNews reports have delivered gains ranging from 100% to over 300% since their respective publication dates. Climb Bio Inc. rose 310% to $12.90 from a published price of $3.14 on December 15, 2025, driven by pipeline progress and positive early clinical data for Budoprutug and CLYM116. Tectonic Therapeutic Inc. gained 121% to $37.93 from $17.15 on October 27, 2025, following positive Phase 1b results for TX45 and initiation of multiple clinical trials. UroGen Pharma Ltd. climbed 280% to $38.02 from $10.01 on April 25, 2025, after FDA approval of Zusduri and strong revenue growth. Eton Pharmaceuticals Inc. advanced 128% to $37.50 from $16.44 on December 11, 2025, supported by FDA approval of DESMODA and multiple commercial deals. Liquidia Corp. surged 249% to $78.93 from $22.59 on October 17, 2025, fueled by the launch and expanding adoption of Yutrepia.
CLYM ▲ETON ▲LQDA ▲TECX ▲URGN ▲
RTTNews·52dRead more ▾
Biotech & Genomic Medicine▲

Non-Muscle Invasive Bladder Cancer Market to Shift as Novel Therapies Enter Late-Stage Development

The non-muscle invasive bladder cancer market is expected to undergo significant transformation during the 2026 to 2036 forecast period as novel targeted and gene therapies advance through late-stage clinical development. The total market size across the seven major markets, comprising the United States, the EU4 countries of Germany, France, Italy, and Spain, the United Kingdom, and Japan, was approximately USD 3 billion in 2025, with the United States holding the largest share. Total prevalent cases of non-muscle invasive bladder cancer in these markets were nearly 1.56 million and are projected to increase by 2036. Key emerging therapies include CG0070 from CG Oncology, EG-70 from enGene, TAR-210 from Janssen, Dabogratinib from Tyra Biosciences, UGN-103 from UroGen Pharma, and TARA-002 from Protara Therapeutics, with cretostimogene grenadenorepvec plus or minus KEYTRUDA expected to generate the highest revenue among all therapies by 2036.
CGON ▲TARA ▲TYRA ▲URGN ▲
Biotech & Genomic Medicine ▲
PR Newswire·64dRead more ▾
© 2026 MarketDXAsset